Stocktoria
Olema Pharmaceuticals, Inc. OLMA
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-11-19
Olema Pharmaceuticals, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| R&D expense | $157.7M | $124.5M | $86.1M | $82.3M | $51.1M | $13.7M |
| Operating income | -$178.7M | -$142.3M | -$105.0M | -$107.0M | -$71.5M | -$21.5M |
| Interest expense | — | — | — | — | — | $653,000 |
| Income tax | $3,000 | $2,000 | $2,000 | $1,000 | — | — |
| Net income | -$162.5M | -$129.5M | -$96.7M | -$104.8M | -$71.1M | -$22.1M |
| EPS (diluted) | $-1.87 | $-2.20 | $-2.14 | $-2.62 | $-1.80 | $-3.42 |
| Operating cash flow | -$146.7M | -$104.4M | -$83.7M | -$82.1M | -$50.7M | -$19.9M |
| Free cash flow | — | -$104.5M | — | -$82.4M | -$52.3M | -$19.9M |
| Cash & equivalents | $48.3M | $139.5M | $68.5M | $23.7M | $13.8M | $338.5M |
| Total assets | $533.4M | $451.0M | $276.9M | $215.6M | $295.9M | $342.7M |
| Total liabilities | $54.9M | $42.0M | $23.1M | $18.1M | $11.4M | $4.6M |
| Shareholders' equity | $478.6M | $409.0M | $253.9M | $197.5M | $284.6M | $338.1M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.